Form 4: Sage Therapeutics Insider Exits Equity Post-Supernus Deal
Rhea-AI Filing Summary
Form 4 highlights: Sage Therapeutics (SAGE) director Geno J. Germano reported the automatic cancellation of 21,500 stock options with a $6.77 exercise price on 07/31/2025, the effective date of Sage’s merger with Supernus Pharmaceuticals. Under the Merger Agreement, each option was deemed fully vested and exchanged for (i) cash equal to the $8.50 per-share tender price minus the $6.77 strike and (ii) one contingent value right (CVR) for each underlying share. Each CVR can pay up to $3.50 in cash if post-closing milestones are met.
Following the conversion, Germano reports zero derivative securities or common shares, indicating a complete exit of equity exposure. Options with strikes at or above $8.50 received no consideration. The filing is administrative in nature and confirms consummation of the cash-and-CVR merger; no new insider purchases or sales of Sage stock occurred on the open market.
Positive
- Merger consummated: Filing confirms closing of Supernus–Sage transaction at $8.50 cash plus CVR.
- Potential upside: Each cancelled option is tied to CVRs that could pay up to $3.50 per share if milestones are achieved.
Negative
- No continuing insider ownership: Director now holds 0 shares/options, eliminating direct insider alignment with any remaining CVR performance.
- Out-of-the-money options cancelled: Options with strikes ≥ $8.50 were extinguished with no payment, reflecting limited residual value for high-strike instruments.
Insights
TL;DR: Insider options cancelled for cash & CVRs due to merger; neutral for valuation.
The disposal is a mechanical outcome of Sage’s takeover by Supernus. Germano’s 21,500 options were cashed out at the $1.73 in-the-money amount and supplemented with CVRs, leaving him with no further stake. Because all minority shareholders received identical terms, the filing does not signal incremental information about Sage’s prospects or merger conditions. Market impact is negligible; valuation hinges on the probability and timing of CVR milestone payments already reflected in deal spreads.
TL;DR: Director’s exit ends insider alignment; limited governance relevance post-merger.
Once Sage merged into Supernus, Sage’s board dissolved; directors no longer require equity alignment. Germano’s reported exit merely documents the mandatory cash-out under the agreement. Investors tracking post-merger integration should focus on Supernus disclosures, not legacy Sage insider filings.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 21,500 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer to purchase all outstanding shares of common stock of the Issuer (each, a "Share") for (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes, and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
